Biotech Stock Mailbag: Geron, Oculus, BioSante
BOSTON, Mass. (TheStreet) -- Readers have been generous with their emails lately. Thank you! And keep your questions coming. I can't answer every email I receive, but I decided to open the Biotech Stock Mailbag early this week in an attempt to whittle down the backlog.
Check back again Friday for the regularly scheduled Mailbag. One more thing: I'm taking a much-needed vacation, so the Mailbag will be on a short hiatus until the first week in September.
Let's get started with an email from Robert B., who writes, "I was wondering what your reaction is (if any) to the FDA's hold on Geron's (GERN) spinal cord therapy. I own some, and not sure how to take the news."
The first thing I did after reading Tuesday's announcement was laugh because the delays and missteps in Geron's over-hyped embryonic stem cell trial for severe spinal cord injuries are pretty much working out the way I thought they would.Ever notice how Geron does a great job of heralding the prospect of scientific achievements and breakthroughs, yet never seems to actually deliver on its promises? In this case, Geron promised to enroll the first paralyzed patients into its stem cell trial during the summer. That announcement was made in January. Yet August is rolling toward a hot and humid finish here in the Northeast, and the study is nowhere close to starting. Last month, the company told investors that car airbags were partly to blame for the delay. (Airbags protect drivers and passengers in accidents, making it hard to find traffic accident victims with paralysis severe enough to be eligible for the clinical trial, or so Geron CEO Tom Okarma said on his company's quarterly conference call.)
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV